Check for updates

CASE REPORT

Case Report: First report of *Elizabethkingia miricola* infection in a patient with cystic fibrosis [version 1; peer review: 2 approved with reservations]

Freddy Frost , Dilip Nazareth

Liverpool Heart & Chest Hospital, Liverpool, L14 3PE, UK

V1 First published: 10 Apr 2018, 7:440
<https://doi.org/10.12688/f1000research.14441.1>
 Latest published: 08 May 2018, 7:440
<https://doi.org/10.12688/f1000research.14441.2>

Abstract

Elizabethkingia miricola is a rare non-fermenting Gram-negative rod that has previously been reported to be associated with blood stream and pulmonary abscess infections, but never before in cystic fibrosis (CF). Here we present the first reported case of *Elizabethkingia miricola* infection in a patient with CF and discuss the management options. We describe a patient with CF in whom we observed clinical and spirometric evidence of pulmonary exacerbation with the associated growth of *E. miricola* in sputum culture. The period of clinical instability was observed to coincide with the obtainment of four sputum samples from which *E. miricola* was cultured; improvement was seen following treatment with ciprofloxacin and the subsequent eradication of *E. miricola*. We conclude that *E. miricola* is able to survive in the CF lung and in this case was associated with pulmonary exacerbation. Empirical treatment with fluoroquinolones is appropriate, based on our experience.

Keywords

Cystic fibrosis, shortness of breath, chest infection, exacerbation, fluoroquinolone

Open Peer Review

Approval Status

	1	2	3
version 2 (revision) 08 May 2018		 view	 view
version 1 10 Apr 2018	 view	 view	

1. **Simon C. Langton Hewer**, Bristol Royal Hospital for Children, Bristol, UK
2. **Andrew M. Jones**, University Hospital of South Manchester, Manchester, UK
3. **Jamie Duckers**, Cardiff and Vale University Health Board, Cardiff, UK

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Freddy Frost (freddy.frost@lhch.nhs.uk)

Author roles: **Frost F:** Conceptualization, Data Curation, Investigation, Writing – Original Draft Preparation, Writing – Review & Editing;
Nazareth D: Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2018 Frost F and Nazareth D. This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Frost F and Nazareth D. **Case Report: First report of *Elizabethkingia miricola* infection in a patient with cystic fibrosis [version 1; peer review: 2 approved with reservations]** F1000Research 2018, 7:440
<https://doi.org/10.12688/f1000research.14441.1>

First published: 10 Apr 2018, 7:440 <https://doi.org/10.12688/f1000research.14441.1>

Introduction

Elizabethkingia miricola, a non-fermenting Gram-negative rod (NFGNB) was first identified following isolation from condensation water in the Russian space laboratory Mir¹. Originally identified as belonging to the *Chryseobacterium* genus, it has since been re-classified and is closely related to *Elizabethkingia meningoseptica* (previously *C. meningosepticum*). *E. miricola* has been demonstrated to be pathogenic, with reports of bacteraemia resulting in sepsis and pulmonary abscesses^{2,3}. Here, we report the presence of *E. miricola* in the sputum of a patient with cystic fibrosis (CF). To our knowledge, this is the first reported case of *E. miricola* infection in CF; herein, we discuss the case itself and the literature surrounding this bacterium to help guide clinicians faced with similar clinical scenarios.

Case report

A 49-year-old male with a diagnosis of CF presented to his routine CF outpatient department complaining of feeling generally unwell. He reported increased cough, but this was non-productive. There was a drop in lung function, from a baseline forced expiratory volume in one second (FEV1) of 2.39 l (65% of the predicted volume) to 2.19 l (60% predicted). A sputum sample was taken and sent for routine culture, but given the non-specific symptoms and mild drop in FEV1, it was agreed that no immediate treatment was required and a follow-up in 4 weeks' time was arranged.

Co-morbidities of the patient included osteoporosis and pancreatic insufficiency; he was also receiving treatment for allergic bronchopulmonary aspergillosis (ABPA). Cultured respiratory samples in the previous year had consistently grown non-epidemic *Pseudomonas aeruginosa*. The diagnosis of CF was made in adulthood and was based the presence of bilateral bronchiectasis on a chest CT scan, a raised chloride level

following a skin sweat test and genetic testing, which revealed that the patient was heterozygous for the CFTR F508del mutation. Family history included a younger sister who had died aged 23 years from pancreatitis.

A sputum sample taken at the clinic appointment was positive for *P. aeruginosa*, and extended incubation isolated *Elizabethkingia miricola*. At the next appointment, worsening symptoms were observed, including increasing shortness of breath, wheeze and productive cough. There was a further drop in FEV1 to 1.91 L (52% predicted) (Figure 1). On the basis of outcomes of previous infective exacerbations, an oral course of chloramphenicol (500 mg four times a day) along with prednisolone (30 mg daily) for 2 weeks was commenced and a further sputum sample was obtained. Sputum culture was again positive for *P. aeruginosa* and *E. miricola*.

A further 4 weeks later, symptoms were somewhat improved and FEV1 lung function had increased to 2.19 l (60% predicted). However, another 2 weeks later, symptoms deteriorated again, with an associated decline in lung function (FEV1, 1.95 l; 53% predicted). Sputum cultures from the previous admission were again positive for *P. aeruginosa* and *E. miricola*. Sensitivities from previous samples revealed *E. miricola* resistant to meropenem and ceftazidime, but sensitive to piperacillin/tazobactam and ciprofloxacin (CIP). A 2-week course of oral CIP (750 mg thrice daily) was therefore commenced.

The patient noted an improvement in symptoms and at the next clinic appointment FEV1 had improved to 2.08 l (57% predicted). Sputum then grew *P. aeruginosa* and yeast only. A further four subsequent sputum samples 1, 4, 8 and 12 months later have grown *P. aeruginosa* but no *E. miricola*, and lung function returned towards baseline.

Figure 1. Lung function before and after positive sputum culture for *Elizabethkingia miricola*. Lung function was measured using forced expiratory volume in one second (FEV1). Dotted lines represent the time period between which four sputum cultures were positive for *E. miricola*.

Discussion

E. miricola has been described in a number of healthcare settings, but not previously in CF. One of the first reports of *E. miricola* infection was of positive growth in blood and sputum cultures of a septic patient whom had recently undergone a stem-cell transplant for mantle-cell lymphoma. Since then it has been reported in only a handful of cases, including septicaemia in a young patient with alcoholic pancreatitis and in the sputum of a septic patient with pulmonary abscesses^{2,3}. More recently, *E. miricola* was identified as causing a UTI in an immunocompetent adult⁴.

Here, we describe a patient with CF in whom we observed clinical and spirometric evidence of pulmonary exacerbation, with associated growth of *E. miricola* in sputum culture. The period of clinical instability was observed to coincide with four sputum samples culturing *E. miricola* and improvement was seen with treatment. This is the first report of *E. miricola* in an individual with CF, meaning this report should therefore be relevant to all CF clinicians and microbiologists involved in the care of people with CF.

All case reports of *E. miricola* infection mentioned above report identification by MALDI-TOF (matrix-assisted laser desorption/ionisation time-of-flight) mass spectrometry^{2–4}. MALDI-TOF has been widely adopted for bacterial identification, facilitating diagnosis quickly and reliably. In the CF setting, MALDI-TOF has also been shown to be particularly useful in identifying non-fermenting gram-negative bacteria, for which classification can be difficult using conventional phenotypic approaches⁵. Given the increasing use of MALDI-TOF in clinical microbiology laboratories, identification of NFGNB infections is likely to rise. Hence, establishing the optimal initial management strategies for these infections is important.

In this case, initial empirical treatment with oral chloramphenicol did not clear the infection, but treatment with oral CIP (based on culture sensitivities) successfully treated the exacerbation.

Eradication of *E. miricola* was also observed, with contemporaneous clinical improvement. Notably, the sputum culture sensitivities revealed that *P. aeruginosa* was resistant to CIP, further supporting the idea that *E. miricola* had a pathogenic role. Our experience of treatment with a fluoroquinolone is in keeping with that of previous reports, in which *E. miricola* bacteraemia has been associated with sensitivity to levofloxacin and/or CIP, both of which resulted in successful treatment^{2,6,7}. Susceptibility to co-trimoxazole (SXT) has also been reported, and it would seem that treatment with fluoroquinolones or SXT is an appropriate empirical strategy.

Conclusion

E. miricola appears to have the potential to grow in the CF lung and can be associated with pulmonary exacerbation. Given the paucity of information on *E. miricola* infection in CF, we hope that the case report and literature review herein are relevant to CF clinicians and microbiologists alike. Treatment based on culture sensitivity is recommended, but empirical treatment with fluoroquinolones may be an appropriate initial strategy if there is suspicion of pathogenicity.

Consent

Written informed consent for the creation and publication of this report was obtained from the patient.

Data availability

All data underlying the results are available as part of the article and no additional source data are required.

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

References

- Li Y, Kawamura Y, Fujiwara N, et al.: *Chryseobacterium miricola* sp. nov., a novel species isolated from condensation water of space station Mir. *Syst Appl Microbiol.* 2003; **26**(4): 523–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Green O, Murray P, Gea-Banacloche JC: Sepsis caused by *Elizabethkingia miricola* successfully treated with tigecycline and levofloxacin. *Diagn Microbiol Infect Dis.* 2008; **62**(4): 430–2.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Gonzalez C, Coolen-Allou N, Allyn J, et al.: [Severe sepsis and pulmonary abscess with bacteremia due to *Elizabethkingia miricola*]. *Med Mal Infect.* 2016; **46**(1): 49–51.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Gupta P, Zaman K, Mohan B, et al.: *Elizabethkingia miricola*: A rare non-fermenter causing urinary tract infection. *World J Clin Cases.* 2017; **5**(5): 187–190.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Alby K, Gilligan PH, Miller MB: Comparison of matrix-assisted laser desorption ionization-time of flight (maldi-tof) mass spectrometry platforms for the identification of gram-negative rods from patients with cystic fibrosis. *J Clin Microbiol.* 2013; **51**(11): 3852–4.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
- Rossati A, Kroumova V, Bargiacchi O, et al.: *Elizabethkingia miricola* bacteriemia in a young woman with acute alcoholic pancreatitis. *Presse Med.* 2015; **44**(10): 1071–2.
[PubMed Abstract](#) | [Publisher Full Text](#)
- Eriksen HB, Gumpert H, Faurholt CH, et al.: Determination of *Elizabethkingia* Diversity by MALDI-TOF Mass Spectrometry and Whole-Genome Sequencing. *Emerg Infect Dis.* 2017; **23**(2): 320–323.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)

Open Peer Review

Current Peer Review Status: ? ?

Version 1

Reviewer Report 30 April 2018

<https://doi.org/10.5256/f1000research.15719.r33065>

© 2018 Jones A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Andrew M. Jones

Manchester Adult Cystic Fibrosis Centre, University Hospital of South Manchester, Manchester, UK

This is the first case described as far as I am aware of *Elizabethkingia mircola* in a patient with cystic fibrosis. The authors describe isolation of *Elizabethkingia mircola* in association with clinical deterioration of a patient, and subsequent clinical improvement and eradication of the organism following quinolone therapy.

The report could be further improved by addressing the points below:

- The authors state in the first paragraph that the patient had a cough that was unproductive, but in contrast also state that a sputum sample was obtained.
- The report states that the patient was receiving treatment for ABPA; it is important to know what exactly the treatment was and in particular if this could have caused immunosuppression and lead to increased susceptibility to unusual infections.
- The authors state the patient was heterozygous for F508del; did they identify the other CF gene?
- The authors state *Elizabethkingia mircola* was isolated after extended incubation: what culture media was used and how long was the extended incubation before *Elizabethkingia mircola* was isolated?

Is the background of the case's history and progression described in sufficient detail?

Partly

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Yes

Is the case presented with sufficient detail to be useful for other practitioners?

Yes

Competing Interests: No competing interests were disclosed.**I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.**

Author Response 01 May 2018

Freddy Frost, Liverpool Heart & Chest Hospital, Liverpool, UK

We are grateful to Professor Jones for his time and review of our case-report. We have moved to clarify the points he has raised. In particular we have reviewed the electronic patient record and clarified that sputum sample was actually obtained by our physiotherapist. We have also expanded on the treatment for ABPA which did include low-dose oral corticosteroids and have discussed the relevance of this in our discussion.

We have confirmed that only one gene was present despite extended genotype screening, but highlighted the reasons for making a robust clinical diagnosis of CF. We have also confirmed that growth was seen on the cepacia selective plate.

Competing Interests: Author of case-report

Reviewer Report 23 April 2018

<https://doi.org/10.5256/f1000research.15719.r33066>

© 2018 Langton Hewer S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Simon C. Langton Hewer

Paediatric Respiratory Medicine, Bristol Royal Hospital for Children, Bristol, UK

I agree that this appears to be the first report of this organism in CF and as such this is a relevant and important article and so should be published. The Case Report para 2 states the patient was heterozygous for CFTR mutation F508del but does not give the other mutation. Readers (including me) would be interested to know the second mutation so this should be stated.

Para 4 states treatment of *P. aeruginosa* and *E. miricola* took place with oral chloramphenicol. This is an unusual choice as *P. aeruginosa* would usually be treated with ciprofloxacin or IV therapies and/or nebuliser amino glycoside. It would be helpful to know why chloramphenicol was chosen and whether any neb antibiotics were used as well (which is likely the case).

These details should be included to give a more complete picture of the case.

Is the background of the case's history and progression described in sufficient detail?

Partly

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Yes

Is the case presented with sufficient detail to be useful for other practitioners?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 24 Apr 2018

Freddy Frost, Liverpool Heart & Chest Hospital, Liverpool, UK

We are very grateful to Dr Langton-Hewer for his review and comments. In response to Dr Langton-Hewer's comments:

- Only one gene was identified despite extended testing. The diagnosis of CF was made based on one gene, raised sweat test, upper lobe bronchiectasis and family history. We have now included more detail with regard to this point.
- Oral chloramphenicol was chosen empirically based on previous response and the patients desire to avoid photosensitivity associated with ciprofloxacin. We have now included more detail in the manuscript.
- Nebulised therapy included Cayston and TOBI, these were continued throughout and we have now included this detail within the manuscript

Competing Interests: Author of case-report

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research